Remegen Co. Ltd. Class A · SSE:688331
Remegen Co. Ltd. Class A — H1 2024 Earnings Presentation
32 slides from Remegen Co. Ltd. Class A's earnings presentation, August 2024
Slide 1: 2024 H1 Results Presentation
2024 H1 Results Presentation August, 2024
Slide 2: Disclaimer
Remecen Disclaimer The documents, opinions and materials presented in this presentation (the “Document” ) have been prepared by RemeGen Co., Ltd. (the “Company” ) for use in presentations by the Company and does not constitute a recommendation regarding the securities of the Company. You fully under
Slide 3: Catalog
CATALOG 01 FINANCIAL SUMMARY 02 CLINICAL DEVELOPMENT 03 COMMERCIALIZATION 04 COMPANY OVERVIEW
Slide 4: Financial Summary
01 FINANCIAL SUMMARY
Slide 5: Key Financial Summary (2024Q1)
Key Financial Summary (2024Q1) Revenue（RMB 000） R&D and Admin Expenses (RMB 000) Research and Development Costs Revenue Gross Profit Administrative Expenses 806,233 739,656 540,453 570,385 419,073 316,418 168,609 155,220 2023H1 2024H1 2023H1 2024H1 ◼ ◼ Selling and Distribution Expenses (RMB 000) Cas
Slide 6: Clinical Development
RemeGen i=} CLINICAL VELOPMENT
Slide 7: Product Pipeline Across Three Therapeutic Areas
Product Pipeline Across Three Therapeutic Areas Development Status by Region 7
Slide 8: Clinical Progress of Telitacicept (RC18)
Clinical Progress of Telitacicept (RC18) Schematic Diagram of Molecular Structure Development Status by Region Dual-targeting Mechanism of Action B A3 B3 Formation of homo/heterotrimers A2B AB2 Telitacicept BCMA BAFF-R TACI APRIL BLyS B cell 8
Slide 9: Telitacicept - Clinical Progress in China (SLE)
Telitacicept - Clinical Progress in China（SLE） SLE（China） Launched in China Efficacy Data of Phase III Study ⚫ ⚫ 9
Slide 10: Telitacicept - Clinical Progress in China (RA)
Telitacicept - Clinical Progress in China （RA） RA（China） Launched in China in July, 2024 Efficacy Data of Phase III Study ⚫ ⚫ 10
Slide 11: Telitacicept - Clinical Progress in China (IgAN)
Telitacicept - Clinical Progress in China （IgAN） IgAN (China） Enrollment completed for the phase III study Efficacy Data of Phase II Trial QMG：-7.7 QMG：-9.6 ⚫ ⚫ ⚫ 11
Slide 12: Telitacicept - Clinical Progress in China (MG)
Telitacicept - Clinical Progress in China （MG） CDE：Breakthrough Therapy Designation MG (China） Efficacy Data of Phase II Trial Phase III clinical trial reached primary endpoints in August, 2024 ⚫ ⚫ 12
Slide 13: Telitacicept - Clinical Progress in China (PSS)
Telitacicept - Clinical Progress in China （PSS） pSS（China） Enrollment completed for the phase III study Efficacy Data of Phase II Trial Placebo Telitacicept 160 mg Telitacicept 240 mg 14 12 ESSDAI(Mean±SE) 10 ⚫ 8 ⚫ 6 ⚫ 4 2 Baseline Week4 Week8 Week12 Week16 Week20 Week24 13
Slide 14: Telitacicept - Global Clinical Trials
Telitacicept - Global Clinical Trials SLE MG Telitacicept IgA Nephritis pSS 14
Slide 15: Telitacicept – New Indications for Domestic and Global Markets
Telitacicept – New Indications for Domestic and Global Markets Aim to become Leading drug for B-cell mediated auto- immune disease 15
Slide 16: Clinical Progress of Disitamab Vedotin (RC48)
Clinical Progress of Disitamab Vedotin（RC48） Development Status by Region MC Val-CitPAB MMAE Antibody Linker Payload UC GC BC 16
Slide 17: Data Continues to Support Disitamab Vedotin Leadership in Urothelial Cancer
Data Continues to Support Disitamab Vedotin Leadership Position in Urothelial Cancer 18
Slide 18: Disitamab Vedotin Shows Promising Potential in Cervical Cancer
Data First Time to Show Promising Potential of Disitamab Vedotin in Cervical Cancer ORR: 36.4% Median PFS: 4.37m(95% CI:2.92, 6.90) CR Overall response, n(%) n=22 CR 1 (4.5) PR 7 (31.8) ORR (95% CI) 36.4 (17.2, 59.3) cORR (95% CI) 31.8 (13.9, 54.9) DCR 19 (86.4) *Based on literature, historical PFS
Slide 19: Disitamab Vedotin (RC48) Global Clinical Progress
Disitamab Vedotin （RC48）Global Clinical Progress Pivotal Study for Second-line Phase III Study of First-line UC UC Patients Patients 19
Slide 20: Clinical Progress of Other Molecules
Clinical Progress of Other Molecules Status（Clinical Sites Indicated on Status Bar）
Slide 21: RC88's First-in-Class Potential Position in Ovarian Cancer
Data to Show RC88’s First-in-Class Potential Position in Ovarian Cancer 18
Slide 22: Commercialization
RemeGen RStV MERCIALIZATION
Slide 23: Commercialization - Telitacicept
Commercialization - Telitacicept（泰爱®） ⚫ Successfully included in the NRDL ⚫ Recruited about 800 experienced sales members ⚫ Listed in over 900 top-grade hospitals in core prefecture-level or above cities ⚫ Covered over 26,000 targeted physicians 22
Slide 24: Commercialization - Disitamab Vedotin
Commercialization - Disitamab Vedotin（爱地希®） ⚫ Successfully included in the NRDL ⚫ Recruited about 600 experienced sales members ⚫ Listed in over 700 top-grade hospitals in core prefecture-level or above cities ⚫ Covered over 25,000 targeted physicians 23
Slide 25: Upcoming Catalysts in 2024
UPCOMING CATALYSTS in 2024 Telitacicept : 01 ✓ China MG Phase III data readout and BLA submission ✓ Global SLE Phase III stage II first patient in. 02 Disitamab Vedotin : ✓ China HER2-expressing breast cancer with liver metastasis BLA submission ✓ Global RC48G001 (RC48+PD-1 in UC) results oral prese
Slide 26: Company Overview
04 COMPANY OVERVIEW
Slide 27: Remegen in a Snapshot
Remegen in a Snapshot Dual-Listed Company Three Technology Platforms Two Commercialized Products Three Therapeutic Areas Full-fledged Biopharma Company 26
Slide 28: Superior Management Team with Strong Track Record
Superior Management Team with Strong Track Record Weidong WANG Dr. Jianmin FANG Dr. Ruyi HE ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ 27
Slide 29: Proven Ability to Transform R&D into Commercialization
Proven Ability to Transform R&D into Commercialization R&D Center Commercialization Facilities Commercialization Team 29
Slide 30: Global Presence
Global Presence Beijing Washington D.C. US Yantai Shanghai South San Francisco, US Hong Kong Adelaide，Australia 1、Headquartered in Yantai 3、Shanghai R&D Centre 5、Rockville, Maryland 7、Hong Kong 2、South San Francisco 4、Beijing 6、Australia 30
Slide 31: Three Core Technical Platforms
Three Core Technical Platforms Antibody Discovery Platform Bi-specific Antibody Antibody-drug Conjugate Platform Platform 32
Slide 32: Questions & Answers
Questions & Answers